

AD _____

Award Number: DAMD17-98-1-8559

TITLE: Estrogen Metabolism and Prostate Cancer Risk

PRINCIPAL INVESTIGATOR: Paola C. Muti, M.D.

CONTRACTING ORGANIZATION: State University of New York
Amherst, New York 14228-2567

REPORT DATE: December 2001

TYPE OF REPORT: Final Addendum

PREPARED FOR: U.S. Army Medical Research and Materiel Command
Fort Detrick, Maryland 21702-5012

DISTRIBUTION STATEMENT: Approved for Public Release;
Distribution Unlimited

The views, opinions and/or findings contained in this report are those of the author(s) and should not be construed as an official Department of the Army position, policy or decision unless so designated by other documentation.

20020910 035

REPORT DOCUMENTATION PAGE

Form Approved
OMB No. 074-0188

Public reporting burden for this collection of information is estimated to average 1 hour per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing this collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden to Washington Headquarters Services, Directorate for Information Operations and Reports, 1215 Jefferson Davis Highway, Suite 1204, Arlington, VA 22202-4302, and to the Office of Management and Budget, Paperwork Reduction Project (0704-0188), Washington, DC 20503

1. AGENCY USE ONLY (Leave blank)

2. REPORT DATE

December 2001

3. REPORT TYPE AND DATES COVERED

Final Addendum (1 Oct 98 - 30 Mar 01)

4. TITLE AND SUBTITLE

Estrogen Metabolism and Prostate Cancer Risk

5. FUNDING NUMBERS

DAMD17-98-1-8559

6. AUTHOR(S)

Paola C. Muti, M.D.

7. PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES)

State University of New York
Amherst, New York 14228-2567

E-Mail: muti@acsu.buffalo.edu

8. PERFORMING ORGANIZATION
REPORT NUMBER

9. SPONSORING / MONITORING AGENCY NAME(S) AND ADDRESS(ES)

U.S. Army Medical Research and Materiel Command
Fort Detrick, Maryland 21702-5012

10. SPONSORING / MONITORING
AGENCY REPORT NUMBER

11. SUPPLEMENTARY NOTES

12a. DISTRIBUTION / AVAILABILITY STATEMENT

Approved for Public Release; Distribution Unlimited

12b. DISTRIBUTION CODE

13. ABSTRACT (Maximum 200 Words)

14. SUBJECT TERMS

Prostate

15. NUMBER OF PAGES

23

16. PRICE CODE

17. SECURITY CLASSIFICATION
OF REPORT

Unclassified

18. SECURITY CLASSIFICATION
OF THIS PAGE

Unclassified

19. SECURITY CLASSIFICATION
OF ABSTRACT

Unclassified

20. LIMITATION OF ABSTRACT

Unlimited

NSN 7540-01-280-5500

Standard Form 298 (Rev. 2-89)
Prescribed by ANSI Std. Z39-18
298-102

Table of Contents

Cover.....	1
SF 298.....	2
Table of Contents.....	3
Introduction.....	4
Material and Methods.....	5-9
Statistical Analysis.....	10
Results.....	11
Conclusions.....	12-14
Acknowledgment.....	15
References.....	16-23

Introduction

Prostate cancer is the most common non-skin cancer among men in industrialized countries (1). The causes of prostate cancer, however, remain largely unknown, with age, race, and family history being the only established risk factors (2). The prostate gland has historically been considered the prototype of an androgen-dependent organ. However, there is evidence that estrogens may induce mitosis of both normal and malignant prostatic epithelial cells in many species, including humans (3,4).

In humans, 16α -hydroxyestrone (16α -OHE1) and estriol are biologically significant estrogens, and their activity can contribute to the overall expression of estrogenic action. Hydroxylation of estrone at the 16α -position, one of the two major and mutually exclusive biotransformation pathways of the estrogens, leads to estrogen metabolites with estrogenic activity (5-7) and genotoxic characteristics (8). The other main pathway for estrogen metabolism is via hydroxylation at the C-2 position, producing 2-hydroxyestrone (2-OHE1), a derivative that has virtually no estrogenic activity (6, 7, 9,10). In addition to the estrogenic effects of the 16α -hydroxylated metabolites, in *in-vivo* models, 16α -hydroxylation of estrone was associated with increased spontaneous incidence of tumors (11).

There is evidence that estrogen metabolism is related to breast cancer risk. Most case-control studies examining these metabolites have shown higher levels of estrone 16α -hydroxylation in breast cancer cases than in healthy controls, particularly for postmenopausal women (12-15). Similarly, two

prospective studies investigating the role of estrogen metabolism as predictor of breast cancer found that study participants with elevated 2-OHE1 /16 α -OHE1 ratio (highest tertile) had a 40% reduction in breast cancer risk compared with those in the lowest tertile (16, 17).

In the present case-control study we examined the association between prostate cancer and estrogen metabolism. Specifically, we tested the hypothesis that the pathway favoring 2-hydroxylation over 16 α -hydroxylation would be associated with a decrease in prostate cancer risk.

Material and Methods

Study Subjects. We conducted a case-control study of incident, primary, histologically confirmed prostate cancer cases in Erie and Niagara counties, NY, USA (the PROMEN study). All participants provided informed consent; the Human Subjects Review Board of the University at Buffalo, School of Medicine and Biomedical Science and each of the participating hospitals approved procedures for protection of human subjects in the study. Prostate cancer patients were men between 45 and 85 years of age. Each prostate cancer case was enrolled in the study and urine was collected soon after diagnosis and before starting any cancer treatment. In addition, because the major focus of the study was the relation of estrogen metabolism to prostate cancer risk, patients on hormonal treatment (current or in the six months prior the diagnosis), or with known metabolic diseases affecting the endocrine profile (i.e., hypogonadism, hyperadrenalism) were excluded. Those affected with chronic or acute liver

diseases were also excluded because of their potential influence on estrogen metabolism. Patients with a previous history of cancer (except of non-melanoma skin cancer) were excluded as well. In addition, because we used driver's license records to identify controls aged 35-65, cases in that age range were also required to have a driver's license. To exclude latent prostate carcinomas that cannot be distinguished from those that would not progress to clinical disease (real latent carcinoma) and those detected in a very early phase of their progression, the present study included only patients with clinically apparent disease (stage B and greater by the staging system proposed by Catalona -18). To standardize the stage of the disease across the hospitals, a screening form developed in the context of the PROMEN study was completed by a trained nurse case-finder using the hospital pathology records. The forms were then reviewed, together with the hospital records, by Dr. Muti, the principal investigator of the study.

Every year, out of a total number of 690 incident prostate cancer cases detected in Erie and Niagara Counties, 450 were identified by the five major hospitals in Buffalo (New York State Cancer Registry). Urologists from two of those major hospitals agreed to fully collaborate with the Promen study and almost all prostate cancer cases were recruited at the Department of Veterans Affairs Medical Center of Western New York Health Care System (VAMC) and the Kaleida Health System (Buffalo General Hospital).

In the course of the study period, from December 1998 to April 2001, 504 prostate cancer cases were identified. Of these 504, 163 met eligibility criteria,

and were approved by the urologists and invited to join the PROMEN study. Of these 163, 50 refused to participate. Thus, among the eligible participants, 70% (113/163) of the subjects participated in the study. Seventeen prostate cancer cases did not provide morning spot of urine thus the present analysis is conducted on 96 subjects.

All prostate cancer cases were adenocarcinomas; 84% showed clinical or imaging evidence of the disease, with the tumor confined within the prostate gland (Stage B). Sixteen per cent of patients had tumors that extended through the gland invading the capsule (Stage C), among those, two patients had distant metastasis.

Control subjects were matched on place of residence (first four digits of the zip code). This matching criterion was introduced to reduce, at least in part, potential systematic differences between prostate cancer cases and controls subjects related to social and life-style factors. Those controls between 35-65 years of age were selected from a list of individuals holding a New York State driver's license and residing in Erie and Niagara Counties. Those aged 65 and over were selected from the rolls of the Health Care Finance Administration. Eligibility criteria for control subjects were the same as for cases. We excluded men on hormonal treatment (current or in the six months prior to the contact), or affected with metabolic or endocrine diseases. Participants with a previous history of cancer (except of non-melanoma skin cancer) were excluded as well. Because there is high prevalence of latent prostate carcinoma in men over age 50 (19, 20), we measured Prostate-Specific Antigen (PSA) in all blood samples

obtained from controls. Controls with a PSA value higher than 4ng/ml were excluded from the control group according to the criterion proposed by the American Cancer Society Prostate Cancer Detection Project (21) until the completion of diagnostic procedures to determine their true case-control status. We identified 8 prostate cancer cases as a result of the PSA determinations in control subjects.

During the study period, 1,373 potential controls were contacted. One hundred and seventy nine of these potential candidates were deceased and 115 were too ill to participate, 293 were not eligible, and we were not able to contact 273 individuals (wrong address, and wrong telephone number). Three hundred and seventeen of the remaining 513 subjects (60%) were enrolled and interviewed. Thirteen men did not provide morning spot of urine, thus the present analysis includes 304 participants.

Hormonal Determinations. For standardization purposes, morning spot urine was collected between 7:00 A.M. and 9:00 A.M. from all participants. The time at specimen collection was recorded. Samples were kept in -80°C freezers until biochemical determinations.

Stored urinary samples from prostate cancer cases and related controls were handled identically and randomly located in the laboratory runs. All laboratory personnel were blinded with regard to case-control status.

Analyses of 2-OHE1 and 16 α -OHE1 were performed using a competitive solid-phase enzyme immunoassay (IMMUNA CARE Corporation, Bethlehem, PA). The urinary estrogen metabolites are found mostly as glucuronide

conjugates and require the removal of the sugar moiety before recognition by the monoclonal antibodies. A mixture of β -glucuronidase and arylsulphatase (glusulase from *H. Pomatia*, Sigma Chemical Co., St. Louis, MO) was used for this purpose. The enzyme digest was then neutralized. Assay incubation time was 3 hours at room temperature. The assay was read kinetically using a Molecular Devices Thermomax plate reader (Molecular Devices, Sunnyvale, CA) and the data were analyzed using SoftMax EIA Application software (Molecular Devices). Both assays have been shown to allow 100% recovery of metabolites with serial dilution and "spiking" of exogenous estrogens into urine samples. The EIA kits have previously been evaluated for validity and reproducibility and the values for each metabolite were compared with values obtained by gas chromatography-mass spectrometry (22-24). As a measure of reproducibility, two laboratory control samples and one sample from the manufacturer were included in all assays; and their values had to fall within two standard deviations from the mean of a continuous Levy-Jennings control plot. In addition, for 10% of the samples duplicates were included twice not identified to the laboratory performing the assay. All samples, standards and controls were assayed in triplicate. Samples that were not within 10% of each other were reassayed. Any sample that was too concentrated or diluted was reassayed at half concentration or 2-4 dilution, respectively. Intra-assay coefficients of variation for 2-OHE1 and 16 α -OHE1 were 3.6% and 3.8%, respectively. Interassay coefficients of variation were 5.9% and 10.2%, respectively.

Statistical Analysis

2-OHE1 and 16 α -OHE1 urinary levels were standardized by the total urinary creatinine. We used unconditional logistic regression to obtain the odds ratios of prostate cancer in relation to estrogen metabolites and their ratio. The independent variables of interest were 2-OHE1, 16 α -OHE1 by tertiles of urine concentration and the 2-OHE1/16 α -OHE1 ratio. We based the cutoff points for each tertile on the distribution of the estrogen metabolites in controls. We identified age, weight, waist-to-hip ratio, race and smoking, as potential covariates according to their potential biologic relevance and logistic regression was used to control for these covariates. In the initial regression model, we examined all variables. Age, weight, waist-to-hip ratio, race and smoking did not substantially modify the results. None of the potential covariates was a confounder of the association between prostate cancer and estrogen metabolites and their ratio. Nevertheless, we included them in further analysis to provide fully adjusted estimates for comparison with those reported in the published literature, in particular with the previous studies on hormones and prostate cancer risk.

We report here the odds ratio and its 95% confidence interval of prostate cancer risk per one unit change in the transformed value. Tests of significance for the continuous variables in the logistic regression models were also used to examine linear trend.

Results

Characteristics of the study population are reported in Table 1. Prostate cancer cases were more likely than control subjects to be slightly younger and heavier and to have higher waist-to-hip ratio and lower education. In a descriptive analysis on control subjects (Table 2) urinary levels of estrogen metabolites did not significantly differ by age strata, by racial groups or waist-to-hip ratio. Lighter subjects had significantly higher levels of 2-OHE1 than heavier men. Current and former smokers had higher concentrations of the estrogen metabolites, with the highest level of 16 α -OHE1 in current smokers.

In Table 3, we show data on prostate cancer risk in relation to tertiles of estrogen metabolites concentrations, their ratio, and their 95% confidence intervals. There was a 20% odds reduction in the highest tertile of the 2-OHE1, however the confidence interval included unity. Conversely, there was increased risk for the highest tertile of 16 α -OHE1 in both the crude and the adjusted point estimates. The odds ratio for the continuous variable was 3.98 (95% CI: 1.01-16.01) for each unit change in the logarithmically transformed value (p for trend = 0.05).

2-OHE1/16 α -OHE1 ratio was associated with a reduction in odds ratios for prostate cancer across tertiles. Odds ratios for the second and third tertiles were 0.87 (95% CI: 0.49-1.54), and 0.60 (95% CI: 0.33-1.11), respectively, with a test for trend of $p=0.05$.

Conclusions

This study appears to indicate that the estrogen metabolism pathway favoring 2-hydroxylation over 16 α -hydroxylation is associated with a reduced risk of prostate cancer risk. To our knowledge this is the first study investigating the effects of estrogen metabolism on prostate cancer risk and the first observation supporting the potential protective role of estrogen metabolites at low biological activity in prostate cancer development.

Epidemiological studies on the effects of estrogens in relation to prostate cancer risk, in particular serum estrone and estradiol have provided conflicting results (25-27). The inconsistency of results may be related to differences in control selection and/or in specimen collection (i.e., control of the sources of hormone variability such as circadian rhythm). It may also be that the relevant measure is not the serum level of estrone and estradiol but rather the estrogen metabolites that we measured in urine.

Serum concentrations of unconjugated estriol and 16 α -OHE1 are low relative to estrone and estradiol (28-29) but their biological impact may be significant because of their lack of affinity for the sex hormone binding globulin (30). In addition, Fishman and colleagues (31, 32) have noted that 16 α -OHE1 can uniquely bind to amino groups on the estrogen receptor, histones, and DNA. First, it is bound as reversible Schiff base then it followed by spontaneous rearrangement to yield a product in which the steroid is covalently linked resulting in a persistent estrogenic responses until the receptor is degraded. In circumstances of comparable hormone secretion, therefore, estradiol metabolism

shifted towards production of 16α -OHE1 could produce a hyperestrogenic milieu, while a predominance of 2-hydroxylation could produce hypoestrogenic conditions. 16α -OHE1 has been found to be elevated in strains of mice susceptible to breast cancer (11). In humans, estrogen metabolism has also been primarily studied in relation to female breast cancer risk (12-17, 33-36).

There are a number of potential explanations for our findings regarding prostate cancer risk, including potential effects of the neoplastic tissue on estrogen metabolism. Prostate cancer tissues and cells are equipped with key enzymes of estrogen metabolism, including hydroxylases, whose activity varies according to estrogen receptor status and responsiveness (37). The differences we observed may be related to the disease processes themselves rather than to etiological differences (37-40).

Another possible source of bias in our study may be related to selection of cases and controls. Because in the studied community prostate cancer is often diagnosed and treated by a large number of private physicians, we were not able to conduct a population-based study. A primary reason for this restriction was that the study entailed specimen collection prior any treatment. As a result, our cases were limited to those attending the largest hospitals in the area, the Department of Veterans Affairs Medical Center of Western New York Health Care System (VAMC) and from Kaleida Health System (Buffalo General Hospital). Our control subjects were selected among residents in Erie and Niagara Counties. Differences in the two populations could bias our results. In order to limit, at least in part, the potential effects of lifestyle bias, the control

subjects were matched on area of residence (neighborhood controls). In addition, because we still observed relevant differences in degree of education between prostate cancer cases and control subjects, we further adjusted for education in the analyses.

In the present study urinary estrogen metabolite levels were determined controlling for several sources of hormone variability both by inclusion criteria and highly standardized conditions at urine collection. Urine samples were collected from prostate cancer cases before cancer treatment was begun, and control subjects were evaluated for potential presence of latent prostate cancer by serum analysis for prostate-specific antigen. Prostate cancer cases and controls with conditions that would alter hormone metabolism were excluded. Care was taken to control for circadian variation in hormone levels. All hormone determinations were performed at the end of the study to reduce technical variability. The laboratory assaying estrogen metabolites was blinded to case-control status. Thus, we minimized potential biases in urine collection and hormone level determination.

In conclusion, this study supports the hypothesis that there is difference in the way estrogens are metabolized between patients affected with prostate cancer and control subjects. Further studies are needed to corroborate these findings that offer the possibility of a new research perspective on role of hormones in prostate cancer development.

Acknowledgment

We thank Mr. Nicholas Willett and Ms. Heidi McCarty for their excellent technical assistance. We also thank the prostate cancer support network groups USTOO and Buffalo Prostate Cancer for their collaboration. Finally, we want to thank all the participants in the study for their generous support of prostate cancer research studies.

References

1. Hsing, AW, Tsao L, Devesa SS (2000) International trends in prostate cancer incidence and mortality. *Int J Cancer* 85:60-67.
2. Nomura AMY, Kolonel LN (1991) Prostate cancer: a current prospective *Am J Epidemiol* 133:200-227.
3. Castagnetta, L., Miceli, M.D., Sorci, C., Pfeffer, U., Farruggio, R., Oliveri, G., Calabrò, M., Carruba, G. (1995) Growth of LNCaP human prostate cancer cells is stimulated by estradiol via its own receptor *Endocrinology* 136:2309-2319.
4. Carruba G, Miceli MD, Comito L, Farruggio R, Sorci CMG, Oliveri G, Amodio R, Di Falco M, D'Amico D, Castagnetta L (1996) Multiple estrogen function in human prostate cancer cells *Ann NY Acad Sci* 784:70-84.
5. Clark JK, Paszko Z, Peck EJ (1977) Nuclear binding and retention of the receptor estrogen complex: relation to the agonist and antagonist properties of estriol *Endocrinology* (199 100:91-96, 1977.
6. Westerlind KC, Gibson KJ, Malone P, Evans GL, Turner RT (1998) Differential effects of estrogen metabolites on bone and reproductive tissues of ovariectomized rats. *J. Bone Mineral Res.*, 13: 1023-1031.

7. Lotun P, Westerlind KC, Turner RT (2001) Tissue-selective effects of continuous release of 2-hydroxyestrone and 16 α -hydroxyestrone on bone, uterus, and mammary gland in ovariectomized growing rats. *J Endocrinol*, 170: 165-174.
8. Telang NT, Suto A, Wong GY, Osborn MP, Bradlow HL (1992) Induction by estrogen metabolite 16 α -hydroxyestrone of genotoxic damage and aberrant proliferation in mouse mammary epithelial cells. *J. Natl. Cancer Inst.*, 84:634-638.
9. Martucci C, Fishman J. (1977) Direction of estradiol metabolism as a control of its hormonal action-uterotrophic activity of estradiol metabolism. *Endocrinology*, 101:1709-1715.
10. Suto A, Bradlow HL, Wong GY, Osborne MP, Telang NT (1993) Experimental down-regulation intermediate biomarkers of carcinogenesis in mouse mammary epithelial cells. *Breast Cancer Res Treat* 27:193-202.
11. Bradlow HL, Hershcopf RJ, Martucci CP, Fishman J (1985) Estradiol 16 α -hydroxylation in the mouse correlates with mammary tumor incidence and presence of murine mammary tumor virus: a possible model for the hormonal etiology of breast cancer in humans. *Proc. Natl Acad Sci USA* 82:6295-6299.

12. Osborne MP, Bradlow HL, Wong GYC, Telang NT (1993) Upregulation of estradiol C16 α -hydroxylation in human breast tissue: a potential biomarker of breast cancer risk. *J Natl Cancer Inst* 85:1917-1920.
13. Ursin G, Londo S, Stanczky FZ, Gentzschein E, Paganini-Hill A, Ross RK, Pike MC (1997) A pilot study of urinary estrogen metabolism (16 α -OHE1 and 2-OHE1) in postmenopausal women with and without breast cancer. *Environ Health Perspect* 105 (Suppl.3):601-605.
14. Kabat GC, Chang CJ, Sparano JA, Sepkovic DW, Hu X-P, Khalil A, Rosenblatt R, Bradlow HL (1997) Urinary estrogen metabolites and breast cancer: a case-control study. *Cancer Epidemiol Biomarkers Prev* 6:505-509.
15. Zheng, W, Dunning L, Jin F, Holtzman, J (1997) Correspondence re: Kabat, G.C., Chang, C.J., Sparano, J.A., Sepkovic, D.W., Hu, X-P, Khalil, A., Rosenblatt, R., Bradlow, H.L. Urinary estrogen metabolites and breast cancer: a case-control study . *Cancer Epidemiol. Biomarkers Prev.*, 6:500-504.

16. Meilahn EN, De Stavola B, Allen DS, Fentiman I, Bradlow HL, Sepkovic, DW, Kuller LH (1998) Do urinary oestrogen metabolites predict breast cancer? Guernsey III cohort follow-up. *Br J Cancer* 78:1250-1255.
17. Muti P, Micheli A, Krogh V, Freudenheim JL, Yang J, Imamura D, Schünemann HJ, Trevisan M, Berrino F (2000) Estrogen metabolism and breast cancer risk. *Epidemiology* 11:635-640.
18. Catalona WJ (1987) Diagnosis, staging, and surgical treatment of prostatic carcinoma. *Arch Intern Med* 147:361-80.
19. Breslow N, Chan CW, Dhorn G (1977) Latent carcinoma of prostate at autopsy in seven areas *Intl J Cancer* 20:680-688.
20. Bostwick, DG, Cooner WH, Denis, L. (1992) The association of benign prostatic hyperplasia and cancer of the prostate. *Cancer*, 70:291-301.
21. Babaian RJ, Mettlin C, Kane R (1992) The relationship of prostate-specific antigen to digital examination and transrectal ultrasonography. Findings of the America Cancer Society National Prostate Cancer Detection Project. *Cancer* 69:1195-1200.
22. Bradlow HL, Sepkovic DW, Klug T, Osborne MP(1998) Application of an improved ELISA assay to the analysis of urinary estrogen metabolites. *Steroids* 63:406-413.

23. Klug TL, Bradlow HL, Sepkovic DW (1994) Monoclonal antibody-based enzyme immunoassay for simultaneous quantitation of 2- and 16 α -hydroxyesterone in urine. *Steroids* 59:648-655.
24. Sepkovic DW, Bradlow HL, Michnovicz J, Murtezani S, Levy I, Osborne MP (1994) Catechol estrogen production in rat microsomes after treatment with indole-3-carbinol, ascorbigen, or B-napthaflavone: A comparison of stable isotope dilution gas chromatography-mass spectrometry and radiometric methods. *Steroids* 59:318-323.
25. Andersson SO, Adami HO, Bergstrom R, Wide L (1993) Serum pituitary and sex steroid hormone levels in the etiology of prostatic cancer - a population based case-control study. *Br J Cancer* 68:97-102.
26. Signorello LB, Tzonou A, Mantzoros CS, Lipworth L, Laggiou P, Hsieh C, Stampfer M, and Trichopoulos D (1997) Serum steroids in relation to prostate cancer risk in a case-control study (Greece) *Cancer Causes and Control*, 8: 632-636.
27. Gann PH, Hennekens CH, Ma J, Longcope C, Stampfer MJ (1996) Prospective study of sex hormone levels and risk of prostate cancer. *J Natl Cancer Inst* 88:1118-1126.

28. Fishman J (1996) The catechol estrogens. *Neuroendocrinology* 22(4):363-374.
29. Longcope C Pratt JH (1977) Blood production rate of estrogens in women with differing ratios of urinary estrogen conjugates. *Steroids* 29:483-488.
30. Fishman J, Martucci C (1980) Biological properties of 16 alpha-hydroestrone: implications in estrogen physiology and pathophysiology. *J Clin Endocrinol Metab* 51:611-615.
31. Swaneck GE, Fishman J (1988) Covalent binding of the endogenous estrogen 16 alpha-hydroxyestrone to estradiol receptor in human breast cancer cells: characterization and intranuclear localization. *Proceedings of the National Academy of Sciences of the United States of America*, 85(21):7831-7835.
32. Yu SC, Fishman J (1985) Interaction of histones with estrogens. Covalent adduct formation with 16 alpha-hydroxyestrone. *Biochemistry* 24(27):8017-8021.
33. Bradlow HL, Hershcopf RJ, Fishman J (1986) Oestradiol 16 α hydroxylase: a risk marker for breast cancer. *Cancer Surv* 5:573-583.

34. Fishman J, Schneider J, Hershcoff RJ, Bradlow HL (1984) Increased estrogen 16 α hydroxylase activity in women with breast and endometrial cancer. *J Steroid Biochem* 20:1077-1081.
35. Castagnetta L, D'Agostino G, Lo Casto M, Traina A, Leake RE (1981) Breast cancer: A comparison of response to endocrine therapy and oestrogen excretion patterns including unusual metabolites. *Br J Cancer* 44:670-674.
36. Castagnetta L, D'Agostino G, Granata OM, Traina A, Leake RE (1983) Studies on oestrogen status and oestrogen hormone sensitivity in advanced endometrial cancer. *In: Steroids and Endometrial Cancer* (Flamigni C., Jasonni V., Nenci I. eds.) New York: Raven Press, pp. 233-236.
37. Stone NN, Fair WR, Fishman J (1986) Estrogen formation in human prostatic tissue from patients with and without benign prostatic hyperplasia. *Prostate*, 9(4):311-318.
38. van Landeghem AAJ, Poortman J, Nabuurs M, Thijssen JHH (1985) Endogenous concentration and subcellular distribution of estrogens in normal and malignant human breast tissue. *Cancer Res* 45:2900-2906.
39. Castagnetta L, Granata OM, Arcuri F, Fecarotta E, Blasi L, Polito L, Carruba G (1992) Recent studies on metabolism and concentrations of

estrogens in breast cancer tissues and cells. *Cancer Detect. Prev.* 16:65-70.

40. Carruba G, Adamski J, Calabrò M, Miceli MD, Cataliotti A, Bellavia V, Lo Bue A, Polito L, Castagnetta L (1997) Molecular expression of 17 β hydroxysteroid dehydrogenase types in relation to their activity in human prostate cancer cells. *Mol Cell Endocrinol* 135:51-57.